Moon and quiet Sun detection with Fermi-LAT observatory

Abstract The Fermi gamma-ray space telescope is an international mission supporting two science instruments, the Gamma-Ray Burst Monitor (GBM), covering the energy range from few keV to 30 MeV, and the Large Area Telescope (LAT), a pair-conversion detector operating at energies from 30 MeV to 300 GeV. The Fermi telescope was successfully launched on June 11, 2008 and has been surveying the sky in gamma rays since August 2008. During the first months of the mission, Fermi has detected high-energy gamma rays from the Moon and quiet Sun since the first weeks of data taking. This emission is produced by interactions of cosmic rays; by nucleons with the solar and lunar surface (albedo), and electrons with solar photons in the heliosphere. The heliospheric emission is produced by inverse-Compton scattering and is predicted to be extended. Both Moon and the quiet Sun was detected by EGRET on CGRO with low statistics, but Fermi is the only gamma-ray mission capable of detecting the Moon and the quiet Sun and monitoring it over the full 24th solar cycle. Here we present the analysis relative to the first months including the observation of the Moon and the Sun, the spectral analysis, the fluxes measurements and finally a comparison with models and previous detections

Gamma-ray emission from the Moon as observed by Fermi

The Large Area Telescope (LAT) on board the Fermi satellite is exploring the gamma-ray sky in the energy range from 20MeV to > 300GeV. Since the start of the science phase of the mission the LAT has detected high-energy gamma rays from the Moon. This emission is produced by interactions of cosmicrays nuclei with the lunar surface and depends on the level of solar activity. Moon was detected by EGRET on CGRO with low statistics, but Fermi is the only gammaray mission capable of detecting the Moon over the full 24th solar cycle. Here we report the detection of gamma-ray emission from the Moon during the first 18 months of observation showing the status of the analysis and interpretation

Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome

The aims of the study were to evaluate head and neck cancer (HNC) patient's compliance to the planned radiation therapy (RT) using the department policy established in 2005 at IPOCFG and to estimate the impact on treatment outcome due to failure in receiving RT as prescribed.info:eu-repo/semantics/publishedVersio

Heparan sulfates facilitate harmless amyloidogenic fibril formation interacting with elastin-like peptides

Heparan sulfates (HSs) modulate tissue elasticity in physiopathological conditions by interacting with various matrix constituents as tropoelastin and elastin-derived peptides. HSs bind also to protein moieties accelerating amyloid formation and influencing cytotoxic properties of insoluble fibrils. Interestingly, amyloidogenic polypeptides, despite their supposed pathogenic role, have been recently explored as promising bio-nanomaterials due to their unique and interesting properties. Therefore, we investigated the interactions of HSs, obtained from different sources and exhibiting various degree of sulfation, with synthetic amyloidogenic elastin-like peptides (ELPs), also looking at the effects of these interactions on cell viability and cell behavior using in vitro cultured fibroblasts, as a prototype of mesenchymal cells known to modulate the soft connective tissue environment. Results demonstrate, for the first time, that HSs, with differences depending on their sulfation pattern and chain length, interact with ELPs accelerating aggregation kinetics and amyloid-like fibril formation as well as self-association. Furthermore, these fibrils do not negatively affect fibroblasts' cell growth and parameters of redox balance, and influence cellular adhesion properties. Data provide information for a better understanding of the interactions altering the elastic component in aging and in pathologic conditions and may pave the way for the development of composite matrix-based biomaterials